Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-Activated prodrug in murine xenograft models of human cancer

Prostate

Volumn 74, Issue 13, 2014, Pages 1308-1319

  Brennen, W Nathaniel ^a   Rosen, D Marc ^a   Chaux, Alcides ^a   Netto, George J ^a   Isaacs, John T ^a   Denmeade, Samuel R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

carcinoma Associated fibroblast (CAF); fibroblast activation protein (FAP); pharmacokinetics; prodrug

Indexed keywords

CARCINOMA-ASSOCIATED FIBROBLAST (CAF); FIBROBLAST ACTIVATION PROTEIN (FAP); PHARMACOKINETICS; PRODRUG;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; GELATINASES; HUMANS; MALE; MEMBRANE PROTEINS; MICE; PRODRUGS; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905909738     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22847     Document Type: Article

References (42)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW,. Cancer genome landscapes. Science 2013; 339 (6127): 1546-1558.
2. Denmeade SR, Isaacs JT,. Engineering enzymatically activated "molecular grenades" for cancer. Oncotarget 2012; 3 (7): 666-667.
3. Denmeade SR, Isaacs JT,. The SERCA pump as a therapeutic target: Making a "smart bomb" for prostate cancer. Cancer Biol Ther 2005; 4 (1): 14-22.
4. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT,. Prostate-specific antigen-Activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003; 95 (13): 990-1000.
5. Janssen S, Rosen DM, Ricklis RM, Dionne CA, Lilja H, Christensen SB, Isaacs JT, Denmeade SR,. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-Activated thapsigargin prodrug. Prostate 2006; 66 (4): 358-368.
6. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Moller JV, Nissen P, Christensen SB, Isaacs JT,. Engineering a prostate-specific membrane antigen-Activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012; 4 (140): 140ra186.
7. Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P,. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011; 59 (5): 747-754.
8. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR,. A prostate-specific antigen-Activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007; 99 (5): 376-385.
9. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR,. Targeting carcinoma-Associated fibroblasts within the tumor stroma with a fibroblast activation protein-Activated prodrug. J Natl Cancer Inst 2012; 104 (17): 1320-1334.
10. Brennen WN, Isaacs JT, Denmeade SR,. Rationale behind targeting fibroblast activation protein-expressing carcinoma-Associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 2012; 11 (2): 257-266.
11. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP, Old LJ,. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 1993; 53 (14): 3327-3335.
12. Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Muller E, Rettig WJ, Gorrell MD,. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999; 29 (6): 1768-1778.
13. O'Brien P, O'Connor BF,. Seprase: An overview of an important matrix serine protease. Biochim Biophys Acta 2008; 1784 (9): 1130-1145.
14. Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, Reich A, Faccin E, Godde S, Dinges H, Muller-Ladner U, Renner C,. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006; 8 (6): R171.
15. Acharya PS, Zukas A, Chandan V, Katzenstein AL, Pure E,. Fibroblast activation protein: A serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol 2006; 37 (3): 352-360.
16. Brennen WN, Denmeade SR, Isaacs JT,. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer 2013; 20 (5): R269-R290.
17. Tchou J, Zhang PJ, Bi Y, Satija C, Marjumdar R, Stephen TL, Lo A, Chen H, Mies C, June CH, Conejo-Garcia J, Pure E,. Fibroblast activation protein expression by stromal cells and tumor-Associated macrophages in human breast cancer. Hum Pathol 2013; 44 (11): 2549-2557.
18. Fearon DT,. The carcinoma-Associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res 2014; 2 (3): 187-193.
19. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT,. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-Alpha. Science 2010; 330 (6005): 827-830.
20. Rosenblum JS, Kozarich JW,. Prolyl peptidases: A serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003; 7 (4): 496-504.
21. Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR,. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 2008; 47 (3): 1076-1086.
22. Christiansen VJ, Jackson KW, Lee KN, McKee PA,. Effect of fibroblast activation protein and alpha2-Antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys 2007; 457 (2): 177-186.
23. Lebeau AM, Brennen WN, Aggarwal S, Denmeade SR,. Targeting the cancer stroma with a fibroblast activation protein-Activated promelittin protoxin. Mol Cancer Thera 2009; 8 (5): 1378-1386.
24. Christensen SB, Skytte DM, Denmeade SR, Dionne C, Moller JV, Nissen P, Isaacs JT,. A Trojan horse in drug development: Targeting of thapsigargins towards prostate cancer cells. Anticancer Agents Med Chem 2009; 9 (3): 276-294.
25. Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE, Christensen SB,. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem 2001; 44 (26): 4696-4703.
26. Singh P, Mhaka AM, Christensen SB, Gray JJ, Denmeade SR, Isaacs JT,. Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase. J Med Chem 2005; 48 (8): 3005-3014.
27. Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR, Isaacs JT,. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Mol Cancer Ther 2009; 8 (5): 1340-1349.
28. Niedermeyer J, Scanlan MJ, Garin-Chesa P, Daiber C, Fiebig HH, Old LJ, Rettig WJ, Schnapp A,. Mouse fibroblast activation protein: Molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer 1997; 71 (3): 383-389.
29. Niedermeyer J, Kriz M, Hilberg F, Garin-Chesa P, Bamberger U, Lenter MC, Park J, Viertel B, Puschner H, Mauz M, Rettig WJ, Schnapp A,. Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol 2000; 20 (3): 1089-1094.
30. Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA,. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006; 107 (4): 1397-1404.
31. Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, Zhao Q, Caballero OL, Larder R, Coll AP, O'Rahilly S, Brindle KM, Teichmann SA, Tuveson DA, Fearon DT,. Depletion of stromal cells expressing fibroblast activation protein-Alpha from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med 2013; 210 (6): 1137-1151.
32. Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, Rosenberg SA,. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 2013; 210 (6): 1125-1135.
33. Davidson GA, Varhol RJ,. Kinetics of thapsigargin-Ca(2+)-ATPase (sarcoplasmic reticulum) interaction reveals a two-step binding mechanism and picomolar inhibition. J Biol Chem 1995; 270 (20): 11731-11734.
34. Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP,. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc Natl Acad Sci USA 1990; 87 (7): 2466-2470.
35. Christensen SB, Andersen A, Kromann H, Treiman M, Tombal B, Denmeade S, Isaacs JT,. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem 1999; 7 (7): 1273-1280.
36. Brennen WN, Chen S, Denmeade SR, Isaacs JT,. Quantification of mesenchymal stem cells (MSCs) at sites of human prostate cancer. Oncotarget 2013; 4 (1): 106-117.
37. Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW, Banerjee D,., Carcinoma-Associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68 (11): 4331-4339.
38. Montero A, Fossella F, Hortobagyi G, Valero V,. Docetaxel for treatment of solid tumours: A systematic review of clinical data. Lancet Oncol 2005; 6 (4): 229-239.
39. Chan S,. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology (Williston Park) 1997; 11 (8 Suppl 8): 19-24.
40. Engels FK, Verweij J,. Docetaxel administration schedule: From fever to tears? A review of randomised studies. Eur J Cancer 2005; 41 (8): 1117-1126.
41. Kintzel PE, Michaud LB, Lange MK,. Docetaxel-Associated epiphora. Pharmacotherapy 2006; 26 (6): 853-867.
42. Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Pure E, Albelda SM,. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2014; 2 (2): 154-166.